文献速递血管炎

抗中性粒细胞胞质抗体相关性血管炎维持缓解治疗模拟模型的开发与验证

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-02-24

研究开发了AAV-Sim微观模拟模型,用于预测抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)维持缓解治疗下的临床结局。内部验证将模型预测的28个月结局与MAINRITSAN2试验比较,外部验证与MAINRITSAN1试验及一项观察性研究比较,模型预测与已发表数据相似。

要点

  • AAV-Sim模拟固定与定制利妥昔单抗再治疗策略下的缓解、复发、感染、终末期肾病和死亡结局。
  • 内部验证中模型预测与MAINRITSAN2试验观察值相似,MAPE范围2%至26%,CV-RMSE为2.3%和2.5%。
  • 外部验证中模型对固定利妥昔单抗再治疗的预测与MAINRITSAN1试验及一项观察性研究表现相似。

核心结论

  • AAV-Sim预测了不同治疗方案的多种临床结局,并已针对已发表数据进行验证。
  • AAV-Sim有潜力为管理指南和研究优先事项提供信息。

研究设计与样本

  • 研究开发了AAV-Sim,一种针对开始维持缓解治疗的AAV个体的临床事件微观模拟模型。
  • 个体在缓解或复发健康状态间转换,并面临严重感染、终末期肾病或死亡风险。
  • 转移率从已发表文献估计,并按个体水平特征分层。
  • 内部验证将模型预测的28个月结局与MAINRITSAN2试验观察结局比较,该试验比较固定与定制再治疗。
  • 外部验证将AAV-Sim固定利妥昔单抗再治疗的结局与MAINRITSAN1试验及一项观察性研究的结局比较。

主要发现

  • 内部验证中,AAV-Sim预测的轻微复发为固定组6.0% vs 定制组7.3%,MAINRITSAN2观察值为6.2% vs 8.6%,MAPE分别为3%和15%。
  • 内部验证中,AAV-Sim预测的主要复发为固定组3.5% vs 定制组5.5%,MAINRITSAN2观察值为3.7% vs 7.4%,MAPE分别为5%和26%。
  • 内部验证中,AAV-Sim预测的严重感染为固定组19.4% vs 定制组11.1%,MAINRITSAN2观察值为19.8% vs 10.2%,MAPE分别为2%和9%。
  • 内部验证中,AAV-Sim预测的无复发生存率为固定组84.8% vs 定制组82.3%,MAINRITSAN2观察值为86% vs 84%,CV-RMSE分别为2.3%和2.5%。
  • 外部验证中观察到相似性能。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论指出AAV-Sim有潜力为管理指南和研究优先事项提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fixed and tailored rituximab retreatment strategies to maintain remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are associated with tradeoffs. The current study was undertaken to develop a simulation model (AAV-Sim) to project clinical outcomes with these strategies. METHODS: We developed the AAV-Sim, a microsimulation model of clinical events among individuals with AAV initiating treatment to maintain remission. Individuals transition between health states of remission or relapse and are at risk for severe infection, end-stage renal disease, or death. We estimated transition rates from published literature, stratified by individual-level characteristics. We performed validation using the mean average percent error (MAPE) and the coefficient of variation of root mean square error (CV-RMSE). In internal validation, we compared model-projected outcomes over 28 months with outcomes observed in the Rituximab versus Azathioprine in ANCA-Associated Vasculitis 2 (MAINRITSAN2) trial, which compared fixed versus tailored retreatment. In external validation, we compared outcomes with fixed rituximab retreatment from the AAV-Sim to outcomes from the MAINRITSAN1 trial and an observational study. RESULTS: The AAV-Sim projected outcomes similar to those in the MAINRITSAN2 trial, including minor (AAV-Sim 6.0% fixed versus 7.3% tailored; MAINRITSAN2 6.2% versus 8.6%; MAPE 3% and 15%) and major relapse (AAV-Sim 3.5% versus 5.5%; MAINRITSAN2 3.7% versus 7.4%; MAPE 5% and 26%), severe infection (AAV-Sim 19.4% versus 11.1%; MAINRITSAN2 19.8% versus 10.2%; MAPE 2% and 9%), and relapse-free survival (AAV-Sim 84.8% versus 82.3%; MAINRITSAN2 86% versus 84%; CV-RMSE 2.3% and 2.5%). Similar performance was observed in external validation. CONCLUSION: The AAV-Sim projected a range of clinical outcomes for different treatment approaches that were validated against published data. The AAV-Sim has the potential to inform management guidelines and research priorities.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wallace ZS, Stone JH, Fu X, et al. Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2023. PMID: 36645017. doi:10.1002/acr.25088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。